Background
==========

In the last several years, a progressive increase in resistance among Gram-negative pathogens has continued unabated. The emergence of multi-drug resistant Gram-negative organisms (MDRGNs) coupled with an alarming scarcity of new antibiotic classes in the pipelines of the pharmaceutical industry has forced the healthcare community to optimize the therapeutic potential of currently available antibiotics \[[@B1]\].

The primary determinant of β-lactam efficacy is the duration of time in which the non-protein bound drugconcentration (fT) exceeds the minimum inhibitory concentration (MIC) of the organism (fT\>MIC) \[[@B2]\]. β-lactam antibiotics have traditionally been administered by intermittent infusion. With intermittent dosing, β-lactams attain a high peak concentration, but short half-lives can lead to precipitous drops in serum drug levels. Optimizing fT\>MIC is particularly difficult for organisms with elevated MICs. Pharmacokinetic studies have shown that prolonging the infusion time provides more consistent serum levels and maximizes fT\>MIC \[[@B3]-[@B7]\]. It is unclear, however, if this translates to improved patient outcomes.

Several trials comparing clinical outcomes of prolonged infusion β-lactams with standard dosing have been completed, with conflicting results \[[@B7]\]. Moreover, the interpretation of these studies remains controversial as most trials were conducted with small numbers of patients. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the efficacy of prolonged infusion β-lactam therapy compared with intermittent infusion β-lactam therapy with regards to mortality, clinical cure, and adverse effects. The primary objective was to determine if prolonged infusion of β-lactam antibiotics resulted in improved patient survival and clinical cure compared to intermittent dosing of β-lactam antibiotics. The secondary objective was to determine if prolonged infusion of β-lactam antibiotics resulted in increased adverse effects compared to standard, bolus dosing of β-lactam antibiotics.

Methods
=======

Definitions
-----------

Prolonged infusion of β-lactam antibiotics consisted of either extended infusion or continuous infusion of the antibiotic. Extended infusions were defined as intermittent infusions lasting ≥ 3 hours, whereas continuous infusion involved administration over a 24-hour period at a fixed rate \[[@B8]\]. Intermittent infusion of β-lactam antibiotics served as the control group and was defined as standard infusions of antibiotics based on package inserts. Identical β-lactams did not need to be administered for both study arms in a particular trial, so long as both drugs were β-lactam antibiotics with similar spectrums of activity.

Outcomes
--------

The primary outcomes of the analysis were mortality and clinical cure. Mortality was assumed to be in-hospital mortality, a biologically relevant period in which death can be considered a consequence of treatment failure. Clinical cure was defined by the discretion of the authors because of the heterogeneous nature of the study population, pathogens involved, and the sites of infections. The secondary outcome of the analysis was adverse effects during β-lactam treatment.

Data sources
------------

Relevant studies were identified from searches of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) without imposing language or study period restrictions. Databases were searched on February 11, 2011 utilizing the final search strategy. Appendix A contains the complete electronic search strategy. Search terms for MEDLINE included descriptors of population, drug, and administration schedule. A similar method was employed to search EMBASE, with different limits to capture clinical trials of humans and to exclude review articles and case reports. Highly sensitive RCT filters were incorporated for MEDLINE and EMBASE searches. For CENTRAL a strategy similar to that used for MEDLINE was utilized, without the highly sensitive term for clinical trials. In addition, due to the smaller size of the CENTRAL database, some terms in the search strategy were altered to increase the sensitivity of the search. Two translators with a medical background were used for any non-English articles encountered. After a final list of included articles was compiled, Web of Science (accessed March 2^nd^, 2011) and a review of the citations for each article were conducted to search for further potentially relevant articles to include. First authors of studies needing further clarification were contacted \[[@B5],[@B9]-[@B12]\].

Study Selection
---------------

Two independent reviewers examined studies for inclusion at both title/abstract and full-text review stages. Any discrepancies between reviewers were resolved by consensus of all study members. During initial title and abstract selection, a broad criterion for inclusion was encouraged and consisted of any study comparing prolonged infusion β-lactams to intermittent β-lactam infusion in humans. Full text review was then conducted with more conservative inclusion requirements. A study was considered eligible if (1) it was an RCT, (2) it compared prolonged infusion β-lactam antibiotics to intermittent β-lactam antibiotics as treatment for hospitalized patients with infections, and (3) it was conducted in humans. Trials focusing on pharmacokinetic or pharmacodynamic parameters with no description of clinical outcomes were excluded. Cross-over RCTs were excluded given concern that this intervention would obscure the benefit of either method of β-lactam administration. Standardized data abstraction forms and risk of bias forms were completed for all included studies.

Data extraction
---------------

Data were extracted by two independent reviewers. Any disagreement was resolved by consensus with the remaining reviewers. The following data were abstracted from each study: study setting and time period, patient ages, baseline APACHE II scores, body sites of infection, and responsible pathogens. Antibiotic name, dose, interval, and duration of infusion, as well as use of additional antibiotics were also recorded. Definition of mortality, clinical cure, adverse effects, and number of participants discontinuing therapy were collected. Extracted data were entered into RevMan version 5.0 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) and a second author independently confirmed accurate data entry into this program.

Methodological quality
----------------------

Two independent reviewers utilized guidelines from the Cochrane Handbook for Systematic Reviews of Interventions to assess manuscript quality \[[@B13]\]. Disagreements were resolved by group consensus. Parameters evaluated included sequence generation, allocation concealment, masking, selective outcome reporting, differential loss to follow-up, and intention-to-treat analysis. The source of the study\'s funding was also documented. If any of this information could not be determined from study description, \"unclear\" was documented.

Data analysis and statistical methods
-------------------------------------

Statistical analyses were performed using RevMan 5.0 software. After a qualitative assessment of heterogeneity, quantitative heterogeneity was assessed by Chi^-^square statistics. The extent of the inconsistencies was characterized using the I^2^statistic. Considerable heterogeneity was indicated by I^2^\>50% \[[@B13]\]. All outcomes were reported as dichotomous. Pooled relative risks (RR) and 95% confidence intervals (CI) for mortality and clinical cure were calculated by use of the Mantel-Haenszel random-effects model given the heterogeneity observed between studies. Publication bias was assessed using funnel plots on mortality and clinical cure endpoints. Sensitivity analyses were performed to test our assumption that inclusion of studies without strict intention-to-treat analysis did not significantly alter results compared to exclusion of these studies. Planned sub-group analyses included the following: continuous infusion β-lactams (excluding extended infusion), β-lactam subclasses, exclusion of pharmaceutical industry funded trials, infections with MDRGNs, and restriction to studies with equivalent total daily dose of β-lactams in both arms. For all analyses, a p-value \< 0.05 was regarded as statistically significant.

Results
=======

Study selection
---------------

We identified 3181 potentially relevant published articles on review of MEDLINE (n = 1884), EMBASE (n = 894), and CENTRAL (n = 403) (Figure [1](#F1){ref-type="fig"}). After removing 181 duplicates, 3000 titles and abstracts were reviewed by two independent study team members. Forty-four studies underwent full text review and 13 met criteria for inclusion. After review of Web of Science and hand searching the citation list of each included study, 1 additional study was included \[[@B14]\]. The baseline characteristics of the 14 included studies are described in Table [1](#T1){ref-type="table"}\[[@B3],[@B4],[@B9],[@B11],[@B14]-[@B23]\].

![**Flow diagram of selection of articles for inclusion in meta-analysis of randomized controlled trials comparing clinical outcomes of prolonged infusion and intermittent infusion of β-lactams in hospitalized inpatients**.](1471-2334-11-181-1){#F1}

###### 

Characteristics of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients

  Study             Country        Setting         Sample Size   Type of Infection                                        Mean Age (range)   Mean APACHE II Score (range)   Definition of Clinical Cure
  ----------------- -------------- --------------- ------------- -------------------------------------------------------- ------------------ ------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------
  Angus 2000        Thailand       Not specified   21            Septicemia, meliodosis                                   NA (27-73)         NA (3-27)                      Not specified
                                                                                                                                                                            
  Bodey 1979        USA            Non-ICU         204           Bacteremia, pneumonia, UTI†, neutropenic Fever           Not specified      Not specified                  Disappearance of all clinical and laboratory evidence of infection at the time administration of antibiotics was discontinued
                                                                                                                                                                            
  Buck 2005         Germany        Non-ICU         24            Various                                                  60.3 (32-88)       Not specified                  Improvement of clinical and laboratory signs of infection: resolution of fever, decreased CRP, normalized leukocytes, CXR resolution
                                                                                                                                                                            
  Georges 2005      France         ICU             50            Pneumonia, bacteremia                                    48.0               Not specified                  Complete resolution of infectious signs without further need for antibiotics
                                                                                                                                                                            
  Hanes 2000        USA            ICU             32            Pneumonia                                                34.5               11.6                           Complete resolution of all signs/symptoms of pneumonia, or improvement in 1+ signs/symptoms of pneumonia
                                                                                                                                                                            
  Kojika 2005       Japan          Not specified   10            Abdominal abscesses                                      63.7 (43-85)       12.5 (9-21)                    Afebrile and normalized white blood cell count
                                                                                                                                                                            
  Lagast 1983       Belgium        Not specified   45            Septicemia                                               Not specified      Not specified                  Disappearance of all clinical and laboratory evidence of infection
                                                                                                                                                                            
  Lau 2006          USA            ICU             262           Abdominal infections                                     49.8 (18-95)       7.9 (0-31)                     Complete resolution of clinical signs and symptoms or improvement (reduction of majority of signs and symptoms and no new signs of infection)
                                                                                                                                                                            
  Lubasch 2003      Germany        Not specified   81            COPD†† exacerbations                                     65.3               Not specified                  Recurrence to situation before exacerbation
                                                                                                                                                                            
  Merchant 2008     USA, Europe    ICU             531           Pneumonia                                                51.5               NA (8-29)                      Microbiologic and clinical response
                                                                                                                                                                            
  Nicolau 2001      USA            ICU             41            Pneumonia, bacteremia                                    51.1               14.7                           Complete resolution of pneumonia or lack of progression of abnormalities on chest radiograph
                                                                                                                                                                            
  Rafati 2006       Iran           ICU             40            Pneumonia, bacteremia, UTIs, SSI, abdominal infections   49                 15.3                           Change in APACHE II score, afebrile, normalization of WBC
                                                                                                                                                                            
  Roberts 2007      Australia      ICU             57            Septicemia                                               47.4               17.6                           Disappearance of all signs and symptoms related to the infection
                                                                                                                                                                            
  Van Zanten 2006   Netherlan ds   Not specified   93            COPD exacerbations                                       66.0 (34-76)       Not specified                  Infiltrate improvement on x-ray, clinical improvement, and no need for antibiotic treatment within 48 h after cefotaxime discontinuation

†Urinary tract infection; ††chronic obstructive pulmonary disease

Study characteristics
---------------------

Study sample sizes varied from 10 to 531 patients. Studies were conducted on at least 4 continents, with the majority in North America or Europe. Year of publication ranged from 1979 to 2008, with all but two studies published after the year 2000 \[[@B15],[@B19]\]. Patients were admitted to the intensive care unit for all or part of their admission in half of the included studies \[[@B4],[@B11],[@B16],[@B20],[@B21]\].

Extended infusion β-lactams were administered in the experimental arm in 3 studies, with the infusion time ranging from 3-7 hours \[[@B14],[@B18],[@B21]\]. The remaining studies included patients receiving continuous infusion β-lactams \[[@B3],[@B4],[@B9],[@B11],[@B15]-[@B17],[@B19],[@B20],[@B22],[@B23]\]. Six studies used the same total daily dose of β-lactams in both study arms \[[@B9],[@B15],[@B17]-[@B20]\]. Table [2](#T2){ref-type="table"} describes the antibiotic dose and infusion schedules in each study. In all studies utilizing a continuous infusion mechanism of β-lactam delivery, a loading dose of the β-lactam was initially administered to ensure early attainment of fT\>MIC. Patients received additional non-β-lactam antibiotics in 11 studies \[[@B4],[@B9],[@B11],[@B14]-[@B17],[@B19],[@B21],[@B22]\]. The medication in the study arms differed in one trial in which doripenem was compared to imipenem \[[@B21]\]. Because of the similar spectrum of activity of these agents, this study was included. Duration of therapy varied markedly between studies with a mean of 9.4 days. In several studies, β-lactam dosing was adjusted for renal insufficiency \[[@B4],[@B11],[@B16],[@B20],[@B24]\].

###### 

Antibiotic dosage and outcome data of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients

                                              Antibiotic Dose and Infusion Schedule   Number Randomized                                Number Analyzed    Adverse Effects                                                                                                       
  ----------------- ------------------------- --------------------------------------- ------------------------------------------------ ------------------ ----------------- ------------------ --------------- ---------------------------------------- ----------------------- --------------------
  **Study**         **Antibiotic**            **Intermittent**                        **Prolonged**                                    **Intermittent**   **Prolonged**     **Intermittent**   **Prolonged**   **Definition**                           **Intermittent n, %**   **Prolonged n, %**
                                                                                                                                                                                                                                                                                
  Angus 2000        Ceftazidime               40 mg/kg q8 h                           4 mg/kg/h over 24 h; 12 mg/kg LD over 30 min\*   11                 10                11                 10              Not specified                            NA                      NA
                                                                                                                                                                                                                                                                                
  Bodey 1979        Cefamandole               3 g q6 h                                12 g over 24 h; 3 g LD over 30 min               92                 74                92                 74              Renal failure                            17 (18)                 14 (19)
                                                                                                                                                                                                                                                                                
  Buck 2005         Piperacillin/Tazobactam   4 g/0.5 g q8 h                          8 g over 24 h; 2 g LD over 60 min                12                 12                12                 12              Not specified                            NA                      NA
                                                                                                                                                                                                                                                                                
  Georges 2005      Cefepime                  2 g q12 h                               2 g q12 h over 12 h                              24                 26                24                 26              Bacterial superinfection                 4 (17)                  3 (12)
                                                                                                                                                                                                                                                                                
  Hanes 2000        Ceftazidime               2 g q8 h                                60 mg/kg over 24 h; 2 g LD over 30 min           15                 17                14                 16              Bacterial superinfection                 3 (22)                  7 (44)
                                                                                                                                                                                                                                                                                
  Kojika 2005       Meropenem                 0.5 g q8 h                              0.5 g q8 h over 3 h                              5                  5                 5                  5               Hepatotoxicity or renal failure          0                       0†††
                                                                                                                                                                                                                                                                                
  Lagast 1983       Cefoperazone              2 g q12                                 4 g over 24 h; 1 g LD over 15 min                25                 20                25                 20              Diarrhea, phlebitis, skin rash           NA                      NA
                                                                                                                                                                                                                                                                                
  Lau 2006          Piperacillin/Tazobactam   3 g/0.375 g q6 h                        12 g/1.5 g over 24 h; 2 g LD over 30 min         132                130               130                128             Gastrointestinal and CNS disturbances    115 (87)                116 (89)
                                                                                                                                                                                                                                                                                
  Lubasch 2003      Ceftazidime               2 g q8 h                                2 g q12 h over 7 h; 2 g LD over 30 min           40                 41                40                 41              Gastrointestinal and CNS disturbances    NA                      NA
                                                                                                                                                                                                                                                                                
  Merchant 2008     Doripenem & Imipenem      Imipenem 500 mg q6 h min;1 g q8 h       Doripenem 500 mg q8 h over 4 h                   267                264               252                249             Hepatotoxicity, diarrhea, rash, nausea   21 (8)                  24 (10)
                                                                                                                                                                                                                                                                                
  Nicolau 2001      Ceftazidime               2 g q8 h                                3 g over 24 h; 1 g LD over 30 min                19                 22                18                 17              Diarrhea, rash                           NA                      NA
                                                                                                                                                                                                                                                                                
  Rafati 2006       Piperacillin              3 g q6 h                                8 g over 24 h; 2 g LD over 30 min                20                 20                20                 20              Not specified                            NA                      NA
                                                                                                                                                                                                                                                                                
  Roberts 2007      Ceftriaxone               2 g q24 h                               2 g over 24 h; 0.5 g LD as \"bolus\"             28                 29                28                 29              Renal failure                            NA                      NA
                                                                                                                                                                                                                                                                                
  Van Zanten 2006   Cefotaxime                1 g q8 h                                2 g over 24 h; 1 g LD over 30 min                46                 47                43                 40              Not specified                            NA                      NA

\*LD - loading dose

Risk of bias within studies
---------------------------

In general, there were few methodologically sound studies with adequate sample sizes to definitively determine whether prolonged infusion β-lactams are superior to intermittent infusion β-lactams for the treatment of infections in hospitalized patients. As outlined in Table [3](#T3){ref-type="table"}, all included studies were RCTs but the method of randomization was detailed in only three trials \[[@B9],[@B11],[@B15]\]. Inclusion and exclusion criteria were clearly defined in all trials. All studies included participants ≥18 years of age, although Angus et al and Hanes et al had younger age limits of 14 years and 16 years, respectively \[[@B3],[@B4]\]. Allocation concealment was implemented in only two studies, as seen in Table [2](#T2){ref-type="table"}\[[@B9],[@B15]\]. The remaining studies largely failed to address allocation concealment. Masking was conducted in only one study \[[@B9]\]. Intention-to-treat analysis was conducted in eight studies \[[@B9],[@B15]-[@B19],[@B21],[@B22]\]. A sensitivity analysis was conducted including only those studies that clearly indicated intention-to-treat analysis to investigate the impact of decreasing methodological quality among studies on our pooled RRs. The quantitative summary measure of effect remained largely unchanged, suggesting that our results were not disproportionately influenced by inclusion of studies not utilizing intention-to-treat analyses (Table [4](#T4){ref-type="table"}).

###### 

Risk of bias assessment of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients

  Study             Funding Source                                      Allocation Sequence Adequately Generated   Allocation Concealment   Masking   Similar Rates of Withdrawals Between Groups   Intention to Treat Analysis
  ----------------- --------------------------------------------------- ------------------------------------------ ------------------------ --------- --------------------------------------------- -----------------------------
  Angus 2000        Wellcome Trust of Great Britain                     Unclear                                    Unclear                  Unclear   Yes                                           No
                                                                                                                                                                                                    
  Bodey 1979        Pharmaceutical company                              Yes                                        Yes                      Unclear   Unclear                                       Yes
                                                                                                                                                                                                    
  Buck 2005         Pharmaceutical company                              Unclear                                    Unclear                  No        Yes                                           Yes
                                                                                                                                                                                                    
  Georges 2005      Not specified                                       Unclear                                    Unclear                  No        Yes                                           Yes
                                                                                                                                                                                                    
  Hanes 2000        Pharmaceutical company                              Unclear                                    Unclear                  Unclear   Yes                                           No
                                                                                                                                                                                                    
  Kojika 2005       Not specified                                       Unclear                                    No                       No        Yes                                           Yes
                                                                                                                                                                                                    
  Lagast 1983       Pharmaceutical company                              Unclear                                    Unclear                  Unclear   Yes                                           Yes
                                                                                                                                                                                                    
  Lau 2006          Pharmaceutical company                              Unclear                                    Unclear                  No        Yes                                           No
                                                                                                                                                                                                    
  Lubasch 2003      Pharmaceutical company                              Unclear                                    Unclear                  No        Unclear                                       Unclear
                                                                                                                                                                                                    
  Merchant 2008     Pharmaceutical company                              Unclear                                    Unclear                  No        Yes                                           Yes
                                                                                                                                                                                                    
  Nicolau 2001      Pharmaceutical company                              Yes                                        Unclear                  No        Yes                                           No
                                                                                                                                                                                                    
  Rafati 2006       Tehran University Medical Sciences Research Board   Unclear                                    Unclear                  No        Yes                                           Yes
                                                                                                                                                                                                    
  Roberts 2007      National Health & Medical Research Council          Yes                                        Yes                      Yes^a^    Yes                                           Yes
                                                                                                                                                                                                    
  Van Zanten 2006   Pharmaceutical company                              Unclear                                    Unclear                  No        No                                            No

^a^Only outcome assessors were masked

###### 

Summary of subgroup and sensitivity analysis of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients†

  --------------------------------------------------------------------------------------------------------------------------
  Sub-group analysis                             Studies\   Mortality\         I^2^%   Studies\   Clinical Cure\     I^2^%
                                                 Included   Risk Ratio (95%\           Included   Risk Ratio (95%\   
                                                            CI)                                   CI)                
  ---------------------------------------------- ---------- ------------------ ------- ---------- ------------------ -------
  β-lactam subclasses                                                                                                

  Penicillins                                    2          0.62 (0.19-2.03)   0       3          0.77 (0.46-1.30)   0

  Cephalosporins                                 4          0.95 (0.35-2.63)   50      8          1.04 (0.92-1.18)   35

  Carbapenems                                    2          1.08 (0.64-1.82)   0       2          1.00 (0.69-1.44)   0

  Continuous infusion                            6          0.80 (0.42-1.50)   22      10         1.01 (0.92-1.10)   16

  Not funded by pharmaceutical industry          5          0.80 (0.37-1.73)   26      5          1.15 (0.85-1.57)   57

  Equivalent daily dose of β-lactam antibiotic   5          1.30 (0.59-2.87)   0       6          1.06 (0.90-1.25)   48

  **Sensitivity-analysis**                                                                                           

  Intention-to-treat analysis                    8          1.10 (0.75-1.60)   0       8          1.05 (0.93-1.19)   21
  --------------------------------------------------------------------------------------------------------------------------

† Reference group is intermittent β-lactam infusion

A pharmaceutical company was identified as the source of funding for nine trials \[[@B3],[@B11],[@B14]-[@B16],[@B19]-[@B21],[@B23]\]. Funnel plots comparing prolonged infusion and intermittent infusion β-lactams were performed to screen for evidence of publication bias for the mortality and clinical cure outcomes (Figure [2](#F2){ref-type="fig"}). For the mortality outcome, the plot suggested a paucity of studies indicating a protective effect of prolonged β-lactam infusion of mortality. A funnel plot evaluating the outcome of clinical cure, however, was relatively symmetrical, suggesting minimal publication bias. Overall, based on qualitative and quantitative exploration, no conclusive evidence of reporting bias was found.

![**Funnel plots demonstrating the possibility of a small publication bias assessing studies reporting mortality (left) but low probability of publication bias assessing studies reporting clinical cure (right) comparing prolonged and intermittent infusion of β-lactam antibiotics in hospitalized patients**.](1471-2334-11-181-2){#F2}

Mortality
---------

Eight studies reported mortality as an outcome (Figure [3](#F3){ref-type="fig"}). Among the 487 patients enrolled in the prolonged infusion β-lactam arm, there were 53 deaths, compared to 56 deaths among the 495 patients in the intermittent infusion arm. These differences were not statistically significant with an RR of 0.92 (95% CI 0.61 - 1.37). The overall I^2^statistic was 9% suggesting relatively low heterogeneity between the studies. Similarly, the Chi-square statistic was 7.66, p = 0.36. All studies except one crossed the null value \[[@B4]\]. Mortality ranged from 2% in a trial consisting of a relatively young population with low severity of illness to 57% in a severely ill population infected with a highly pathogenic organism, *Burkholderia pseudomallei*\[[@B4],[@B20]\]. Only one study demonstrated a mortality advantage to prolonged infusion β-lactams \[[@B4]\]. This was the only study in which all included subjects were in critical condition and had bacterial cultures confirming infection with a resistant Gram-negative organism.

![**Mortality comparing prolonged infusion and intermittent infusion of β-lactam antibiotics in hospitalized patients**.](1471-2334-11-181-3){#F3}

Because of an *a priori*hypothesis that certain β-lactams may be more effective with prolonged infusion mechanisms than others, subgroup analysis of each of the β-lactam subclasses was conducted. This hypothesis was based on the observation that some β-lactams, like piperacillin, have a MIC breakpoint higher than postulated to be effective based on Monte Carlo simulation techniques \[[@B8]\]. No significant differences were found between subclasses, although each of these subgroups was relatively small. Similarly, subgroup analyses including only studies that used continuous infusion β-lactams, only non-pharmaceutical industry sponsored trials, and only studies utilizing equivalent total daily β-lactam dose in both study arms did not yield results different from the pooled RR derived from inclusion of all studies (Table [4](#T4){ref-type="table"}). A subgroup analysis was planned for studies with highly resistant organisms, but the MIC for organisms was not reported in the vast majority of trials, precluding completion of this subgroup analysis.

Clinical cure
-------------

All but one study included clinical cure as an outcome (Figure [4](#F4){ref-type="fig"}) \[[@B4]\]. Proportion of clinical cure ranged from 32% to 100%. In the prolonged arm, 470 out of 677 evaluable patients were considered clinical successes. This compared to 479 out of 703 in the standard infusion arm. The pooled RR was 1.00 (95% CI 0.94-1.06). The I^2^statistic was 0%, and similarly the Chi-square statistic did not indicate heterogeneity (p = 0.58). Similar to mortality, no significant difference was observed in clinical success between prolonged infusion and intermittent infusion β-lactam antibiotics. Only one study demonstrated a statistically significant clinical cure outcome, favoring the prolonged infusion arm \[[@B9]\]. Of importance, this was the only study in which the allocation sequence was adequately generated, allocation concealment was appropriate, some degree of blinding occurred, and appropriate intention to treat analysis was utilized. Subgroups for clinical cure were analyzed in the same manner as mortality, with results that were similar to pooled estimates as displayed in Table [4](#T4){ref-type="table"}.

![**Clinical cure comparing prolonged infusion and intermittent infusion of β-lactam antibiotics in hospitalized patients**.](1471-2334-11-181-4){#F4}

Adverse effects
---------------

Six studies reported adverse effects during administration of the study medication. The most common reported adverse effects were diarrhea and hepatotoxicity. For almost all studies, the inclusion criteria for adverse effects were not developed *a priori*. The definition of adverse effects varied substantially between studies preventing calculation of a meaningful pooled RR ratio (Figure [5](#F5){ref-type="fig"}).

![**Adverse effects comparing prolonged and intermittent infusion of β-lactam antibiotics in hospitalized patients**.](1471-2334-11-181-5){#F5}

Study withdrawals
-----------------

Differential losses to follow-up appeared to be minimal, as rates of study withdrawals were relatively similar between study arms (Figure [6](#F6){ref-type="fig"}). No study reported greater than 12% study withdrawal. \[[@B3],[@B4],[@B9],[@B16]-[@B22],[@B24]\] Because of the scarcity of details regarding reasons for withdrawals, a summary statistic for withdrawals was not calculated.

![**Study participant withdrawals comparing prolonged and intermittent infusion of β-lactam antibiotics in hospitalized patients**.](1471-2334-11-181-6){#F6}

Discussion
==========

Several observational studies with varying study designs comparing clinical benefits of prolonged and intermittent infusion of β-lactam antibiotics have been conducted with inconsistent results. A prospective study of 98 hospitalized patients who were prescribed piperacillin-tazobactam revealed a trend towards greater clinical success in the continuous infusion group when compared with intermittent infusion recipients \[[@B25]\]. In a retrospective cohort study of piperacillin-tazobactam for *Pseudomonas aeruginosa*sepsis, a significantly lower 14-day mortality rate and shorter hospital length of stay in patients receiving extended infusion, was demonstrated \[[@B26]\]. Results from another retrospective cohort study showed increased clinical cure by continuous versus intermittent infusion of piperacillin-tazobactam in adults with ventilator-associated pneumonia (VAP) caused by Gram-negative pathogens with MICs ≥8 μg/ml \[[@B27]\]. A third retrospective cohort study, however, failed to demonstrate improved clinical outcomes with extended infusion piperacillin-tazobactam \[[@B28]\]. Drug-related adverse effects were mild and reported in similar numbers in both treatment arms in all of these studies \[[@B25]-[@B28]\]. Retrospective studies comparing continuous infusion versus intermittent infusion cefepime and meropenem in patients with VAP both noted significantly improved clinical cure rates in the continuous infusion arms \[[@B29],[@B30]\].

In an attempt to clarify the comparative effect of prolonged versus intermittent infusion β-lactam antibiotics on mortality, clinical cure, and adverse effects, we analyzed RCTs that offered the most methodologically rigorous evidence from the available studies. Our results do not demonstrate a clinical advantage to prolonged infusion β-lactams for routine use in hospitalized patients. Sensitivity analyses and various sub-group analyses determined by *a priori*biologically-plausible hypotheses similarly did not indicate an advantage to prolonged infusion β-lactams.

Two previous systematic reviews and meta-analyses were published to answer similar questions \[[@B31],[@B32]\]. A previous meta-analysis included continuous infusion of aminoglycosides and vancomycin, making it difficult to isolate the benefit of β-lactams \[[@B32]\]. A prior systematic review focused on continuous infusion β-lactams in the prolonged arm and included cross-over studies \[[@B31]\]. *In vitro*evidence demonstrates similar properties of fT\>MIC for both extended and continuous infusion β-lactams making their effect likely comparable, thus we elected to include both groups under the umbrella term \"prolonged infusion,\" a decision that was further supported by our sub-group analysis of only studies examining continuous β-lactam infusions. Inclusion of cross-over studies obscures clinical benefits attributable to the different infusion schedules, and therefore these studies were excluded in the present review. The current meta-analysis includes two additional RCTs, consisting of 612 patients, compared with those published previously \[[@B14],[@B21]\]. Overall, the findings of our meta-analysis are consistent with those previously described \[[@B31],[@B32]\].

Our study has several limitations that should be taken into account when interpreting the results. Overall, the included studies were of moderate to poor quality with regards to answering our clinical question of interest and had notable methodological differences. Allocation sequence generation and allocation concealment were not addressed in most studies. As a result, most of these studies were at risk for selection bias. Similarly, most of the studies did not adequately address masking, making detection bias a consideration. Although masking of health care providers and patients may be difficult to impose because of the nature of the intervention, masking of outcome assessors would certainly be reasonable. Of interest, the study with the most stringent methods was the only one to show a clinical cure advantage for prolonging β-lactam infusions \[[@B9]\]. Most trials were funded by the pharmaceutical industry, making reporting bias a concern. Studies conducted by the pharmaceutical industry with unfavorable results for prolonged infusion β-lactams may be less likely to be published \[[@B33]\].

Another noteworthy limitation is that participants in the available studies were frequently receiving additional antibiotics, generally aminoglycosides, limiting conclusions about the sole contribution of the β-lactam antibiotics. In reality, however, when prolonged β-lactams are administered, it is generally a final attempt to rid the body of a particular pathogen and is administered in conjunction with aminoglycoside therapy, making the design of several of these studies similar to actual clinical practice \[[@B7]\]. Only six of the studies used the same total daily dose of β-lactam antibiotic in both arms \[[@B8],[@B9],[@B15],[@B17]-[@B19]\]. The majority of studies used a higher dose of antibiotic in the intermittent infusion arm and this unequal treatment favoring standard infusions could have biased the results towards the null. Subgroup analysis of studies with equivalent total daily dose of β-lactam antibiotic in both arms was conducted and did not demonstrate any significant results; however, interpretation of these results is limited by the relatively small sample size of this population and the notable heterogeneity of these trials (I^2^=50%).

Perhaps the biggest limitation to our study is that the bacterial isolates identified in the included RCTs generally had MICs in the susceptible range. Little difference exists between intermittent and prolonged administration of β-lactams in achieving fT\>MIC in this range of susceptibility \[[@B2]\]. However, when less susceptible organisms are present, the likelihood for treatment failure increases with intermittent dosing. In one study, maintaining a fT\>MIC of 100% for cephalosporins was associated with significantly improved clinical cure compared to maintenance of fT\>MIC at lower percentages \[[@B34]\]. Prolonged infusion therapy is generally considered in clinical scenarios involving MDRGN organisms with elevated MICs. From the available RCTs, it cannot be determined if prolonged infusion β-lactams result in greater clinical success than standard β-lactam infusions when MDRGNs are the offending pathogens. Interestingly, the one study conducted in critically ill patients with microbiological evidence of a resistant Gram-negative organism did in fact show a mortality benefit in favor of prolonged β-lactam administration \[[@B4]\]. Perhaps, inclusion of studies with a low burden of disease and highly susceptible microorganisms in our review may have diluted the true effect of prolonged antibiotic infusion regimens.

Despite these limitations, this systematic review and meta-analysis add useful information to the literature. The 14 included studies span 4 continents and are not restricted to the English language, thus increasing generalizability. As only RCTs were included, baseline characteristics including age, severity of illness, body site of infection, responsible pathogens, and underlying medical conditions were similar between the treatment groups. Confounding by indication can be extremely problematic in observational studies, as prognostic factors may influence treatment decisions. However, this was unlikely in the included trials because of the process of randomization.

Optimizing the pharmacokinetics-pharmacodynamics of currently available antibiotics is necessary in the era of MDRGN infections. Known β-lactam pharmacodynamics support the concept of prolonged infusion to maximize fT\>MIC, but limited clinical data exist regarding the comparative efficacy of prolonged β-lactam infusion. The results of this meta-analysis do not support an advantage to the use of prolonged infusion β-lactam antibiotics as standard practice for hospitalized patients. These findings remained consistent in the multiple sensitivity and subgroup analyses that were evaluated.

Conclusions
===========

Prolonged infusion β-lactam antibiotics may have value in a specific subsets of patients, such as those with highly-resistant Gram-negative infections because of exploitation of their property of fT\>MIC. Unfortunately, the very limited number of patients in the included RCTs with MDRGNs precluded evaluation of this subgroup in the present meta-analysis. Methodologically rigorous studies analyzing prolonged infusion β-lactams for critically ill patients with MDRGN infections are necessary to substantiate this potential benefit.
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Endnotes
========

APPENDIX: Final Electronic Search Strategy (February 11, 2011)
--------------------------------------------------------------

### MEDLINE Search Strategy

((\"beta-lactams\"\[MeSH\] OR \"beta-lactams\"\[tiab\] OR \"beta lactam\"\[tiab\]) AND (\"anti-bacterial agents\"\[MeSH\] OR (\"anti-bacterial\"\[tiab\] AND \"agents\"\[tiab\]) OR \"anti-bacterial agents\"\[tiab\] OR \"antibiotics\"\[tiab\] OR \"antibiotic\"\[tiab\]) OR \"beta-lactam antibiotics\"\[tiab\] OR \"beta-lactam antibiotic\"\[tiab\] OR doripenem\[Title/Abstract\] OR cefepime\[Title/Abstract\] OR ceftazidime\[Title/Abstract\] OR piperacillin\[Title/Abstract\] OR piperacillin/tazobactam\[tiab\] OR piperacillin-tazobactam\[tiab\] OR cefamandole\[tiab\] OR cefazolin\[tiab\] OR cefotaxime\[tiab\] OR ceftriaxone\[tiab\] OR imipenem\[tiab\] OR meropenem\[tiab\] OR ertapenem\[tiab\] OR cefoperazone\[tiab\] OR penicillin\[tiab\] OR penicillins\[tiab\] OR imipenem-cilastatin\[tiab\] OR ampicillin\[tiab\] OR ampicillin-sulbactam\[tiab\] OR sulbactam-ampicillin\[tiab\] OR tazocin\[tiab\] OR carbenicillin\[tiab\] OR carbapenem\[tiab\] OR cephalosporin\[tiab\] OR cephalosporins\[tiab\] OR ticarcillin-clavulanate\[tiab\] OR cefpirome\[tiab\] OR flucloxacillin\[tiab\] OR mezlocillin\[tiab\] OR aztreonam\[tiab\] OR cefuroxime\[tiab\] OR ceftizoxime\[tiab\])

AND

(\"Drug Administration Schedule\"\[Mesh\] OR \"Infusions, Intravenous\"\[MeSH\] OR \"continuous infusion\"\[Title/Abstract\] OR \"extended infusion\"\[Title/Abstract\] OR \"intermittent therapy\"\[Title/Abstract\] OR ((continuous\[tiab\] OR bolus\[tiab\] OR extended\[tiab\] OR intermittent\[tiab\]) AND (administration\[tiab\] OR infusion\[tiab\] OR dosing\[tiab\])))

AND

(\"hospitalized\"\[tiab\] OR \"hospitalised\"\[tiab\] OR \"hospitalization\"\[tiab\] OR \"hospitalisation\"\[tiab\] OR \"Bacterial Infections\"\[Mesh\] OR \"sepsis\"\[Title/Abstract\] OR ((\"intensive\"\[tiab\] OR \"critical\"\[tiab\] OR \"acute\"\[tiab\]) AND (\"care\"\[tiab\] OR \"unit\"\[tiab\] OR \"illness\"\[tiab\])))

AND

(randomized controlled trial\[pt\] OR controlled clinical trial\[pt\] OR randomized\[tiab\] OR placebo\[tiab\] OR drug therapy\[sh\] OR randomly\[tiab\] OR trial\[tiab\] OR groups\[tiab\] NOT (animals\[mh\] NOT humans\[mh\]))

### Cochrane Search Strategy

((\"beta-lactams\"\[MeSH\] OR \"beta-lactams\"\[all fields\] OR \"beta lactam\"\[all fields\]) AND (\"anti-bacterial agents\"\[MeSH\] OR (\"anti-bacterial\"\[all fields\] AND \"agents\"\[all fields\]) OR \"anti-bacterial agents\"\[all fields\] OR \"antibiotics\"\[all fields\] OR \"antibiotic\"\[all fields\]) OR \"beta-lactam antibiotics\"\[tiab\] OR \"beta-lactam antibiotic\"\[tiab\] OR doripenem\[Title/Abstract\] OR cefepime\[Title/Abstract\] OR ceftazidime\[Title/Abstract\] OR piperacillin\[Title/Abstract\] OR piperacillin/tazobactam\[tiab\] OR piperacillin-tazobactam\[tiab\] OR cefamandole\[tiab\] OR cefazolin\[tiab\] OR cefotaxime\[tiab\] OR ceftriaxone\[tiab\] OR imipenem\[tiab\] OR meropenem\[tiab\] OR ertapenem\[tiab\] OR cefoperazone\[tiab\] OR penicillin\[tiab\] OR penicillins\[tiab\] OR imipenem-cilastatin\[tiab\] OR ampicillin\[tiab\] OR ampicillin-sulbactam\[tiab\] OR sulbactam-ampicillin\[tiab\] OR tazocin\[tiab\] OR carbenicillin\[tiab\] OR carbapenem\[tiab\] OR cephalosporin\[tiab\] OR cephalosporins\[tiab\] OR ticarcillin-clavulanate\[tiab\] OR cefpirome\[tiab\] OR flucloxacillin\[tiab\] OR mezlocillin\[tiab\] OR aztreonam\[tiab\] OR cefuroxime\[tiab\] OR ceftizoxime\[tiab\])

AND

(\"Drug Administration Schedule\"\[Mesh\] OR \"Infusions, Intravenous\"\[MeSH\] OR \"continuous infusion\"\[Title/Abstract\] OR \"extended infusion\"\[Title/Abstract\] OR \"intermittent therapy\"\[Title/Abstract\] OR ((continuous\[tiab\] OR bolus\[tiab\] OR extended\[tiab\] OR intermittent\[tiab\]) AND (administration\[tiab\] OR infusion\[tiab\] OR dosing\[tiab\])))

AND

(\"inpatient\"\[mesh\] OR \"hospitalized\"\[tiab\] OR \"hospitalised\"\[tiab\] OR \"hospitalization\"\[tiab\] OR \"hospitalisation\"\[tiab\] OR \"Bacterial Infections\"\[Mesh\] OR \"sepsis\"\[Title/Abstract\] OR ((\"intensive\"\[tiab\] OR \"critical\"\[tiab\] OR \"acute\"\[tiab\]) AND (\"care\"\[tiab\] OR \"unit\"\[tiab\] OR \"illness\"\[tiab\])))

### EMBASE Search Strategy

(\'hospital patients\':ab,ti OR \'hospitalized patients\':ab,ti OR \'hospitalised patients\':ab,ti OR \'hospital infection\'/exp OR (\'sepsis\':ab,ti) OR (\'septicemia\':ab,ti) OR (\'septic shock\':ab,ti) OR (\'bacterial infection\'/exp) OR (\'critically ill patient\':ab,ti) OR (\'critically ill patients\':ab,ti) OR (\'critical illness\':ab,ti) OR (\'systemic inflammatory response syndrome\':ab,ti))

AND

((\'beta lactams\'/exp) OR \'doripenem\':ab,ti OR \'cefepime\':ab,ti OR \'ceftazidime\':ab,ti OR \'piperacillin\':ab,ti OR \'piperacillin tazobactam\':ab,ti OR \'piperacillin\':ab,ti OR \'piperacillin tazobactam combination product\':ab,ti OR \'tazobactam\':ab,ti OR \'cefamandole\':ab,ti OR \'cefazolin\':ab,ti OR \'cefotaxime\':ab,ti OR \'ceftriaxone\':ab,ti OR \'imipenem\':ab,ti OR \'meropenem\':ab,ti OR \'ertapenem\':ab,ti OR \'cefoperazone\':ab,ti OR \'penicillin\':ab,ti OR \'penicillins\':ab,ti OR \'imipenem-cilastatin\':ab,ti OR \'ampicillin\':ab,ti OR \'ampicillin-sulbactam\':ab,ti OR \'sulbactam-ampicillin\':ab,ti OR \'tazocin\':ab,ti OR \'carbenicillin\':ab,ti OR \'carbapenem\':ab,ti OR \'cephalosporin\':ab,ti OR \'cephalosporins\':ab,ti OR \'ticarcillin-clavulanate\':ab,ti OR \'cefpirome\':ab,ti OR \'flucloxacillin\':ab,ti OR \'mezlocillin\':ab,ti OR \'aztreonam\':ab,ti OR \'cefuroxime\':ab,ti OR \'ceftizoxime\':ab,ti)

AND

(\'drug administration\'/exp OR \'intravenous drug administration\'/exp OR \'drug intermittent therapy\'/exp OR (\'continuous infusion\':ab,ti) OR (\'extended infusion\':ab,ti) OR \'intermittent therapy\':ab,ti OR ((\'continuous\':ab,ti OR \'bolus\':ab,ti OR \'extended\':ab,ti OR \'intermittent\':ab,ti) AND (\'administration\':ab,ti OR \'infusion\':ab,ti OR \'dosing\':ab,ti)))

AND

(((\'randomized controlled trial\'/exp OR \'clinical trial\'/exp) OR (\'randomization\'/exp)))

AND

\[humans\]/lim

AND

NOT (\'review\'/exp OR review)
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